The human proteins APOBEC3F and APOBEC3G restrict retroviral infection by deaminating cytosine residues in the first cDNA strand of a replicating virus. These proteins have two putative deaminase domains, and it is unclear whether one or both catalyze deamination, unlike their homologs, AID and APOBEC1, which are well characterized single domain deaminases. Here, we show that only the C-terminal cytosine deaminase domain of APOBEC3F and -3G governs retroviral hypermutation.
The infectivity of a number of diverse retroviruses can be restricted by the human cellular proteins APOBEC3F 1 and APOBEC3G, including HIV-1, simian immunodeficiency virus, equine infectious anemia virus, and murine leukemia virus (1-7). For HIV-1 restriction, several distinct steps are required (8) . First, APOBEC3F and -3G must escape inactivation by the viral infectivity factor, Vif, which targets them for proteosomal degradation (9 -15) . Escape may be facilitated by the fact that APOBEC3F can partially resist HIV-1 Vif (4, 6) . Second, APOBEC3F and -3G can independently, and possibly coordinately, gain access to the assembling viral particle through an association with the nucleocapsid region of Gag and viral genomic RNA (16 -22) . Third, once the virus infects a new cell, APOBEC3F and -3G deaminate nascent retroviral cDNA cytosines to uracils (1) (2) (3) (4) (5) (6) (7) . These lesions manifest as genomic strand guanine to adenine hypermutations and can occur at strikingly high frequencies. Despite similar mechanisms of action and high levels of amino acid identity, APOBEC3F and -3G elicit distinct minus strand mutational preferences, 5Ј-TC and -CC, respectively (5Ј-GA and -GG on the viral genomic strand). Clear examples of both types of hypermutation occur in patient-derived HIV-1 DNA sequences indicating that these proteins are at least some of the time able to escape Vif-mediated degradation in vivo (4, 23) .
Human APOBEC protein family members have either one or two cytosine/cytidine deaminase domains, each defined by a conserved HXE-X 23-28 -CPX 2-4 C motif (8, 24 -26) . Based on the three-dimensional structures of bacterial and yeast cytidine deaminases, the histidine and the cysteine residues are proposed to coordinate a zinc ion, whereas the glutamate promotes the creation of a hydroxide ion critical for deamination. The apoB mRNA editing protein APOBEC1 and the antibody gene deaminase AID are examples of single domain cytosine deaminases, and their activity is abolished by the mutation of the conserved deaminase domain residues (8, 26 -28) . In contrast, APOBEC3F and -3G have two deaminase domains, both of which appear to be essential for retroviral restriction (1, 3, 29) . However, it is not presently clear whether one or both of these domains participates directly in the deamination reaction itself.
Here, we took advantage of the distinct dinucleotide hypermutation preferences of APOBEC3F and -3G (5Ј-TC and -CC, respectively) to show that this preference and the associated cytosine deaminase activity track exclusively with the C-terminal deaminase domain. The N-terminal deaminase domain was not required for C3 U conversion, and it is likely important for other aspects of this innate retroviral restriction mechanism.
MATERIALS AND METHODS
Plasmid Constructions-Escherichia coli expression plasmids were derived from pTrc99A (AP BioSciences). The APOBEC3G expression construct was made by amplification of the human APOBEC3G cDNA from pRH204 (30) using oligonucleotides 431 and 365 (5Ј-NNG AGC  TCA GGT ACC ACC ATG AAG CCT CAC TTC AGA AAC-3Ј and  5Ј-NNN NGT CGA CCC CAT CCT TCA GTT TTC CTG-3Ј) and digestion of the PCR product with KpnI and SalI followed by ligation into pTrc99A. The human APOBEC3F expression plasmid was described previously (4) , and this insert was flanked by identical restriction sites. The A3FϩG and A3GϩF chimeras were constructed by restricting the aforementioned plasmids with BsrG1, which cuts each APOBEC cDNA * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
internally (Fig. 1A) , and with either KpnI or SalI. Ligation of these plasmid backbones with the corresponding inserts produced A3F(1-162)ϩA3G(168 -384) and A3G(1-167)ϩA3F(163-373), respectively. The A3FϩAID expression plasmid was constructed by PCR amplification of the N-terminal region of APOBEC3F using oligonucleotides 431 and 459 (5Ј-G TAA AGA AAC TTC CTC CGG TTC ATT GCC TCC ATC GGG-3Ј) and PCR amplification of AID using oligonucleotides 369 and 245 (5Ј-NN NNC CAT GGA CAG CCT CTT GAT GAA-3Ј and 5Ј-NNG GAT CCT GCA GTC AAA GTC CCA AAG TAC GAA ATG-3Ј), gel purification of the resulting products, followed by a second PCR amplification primed by complementary sequences within each product, and finally a third PCR amplification of the full-length chimeric cDNA using the 5Ј-APOBEC3F oligonucleotide 431 and the 3Ј-AID oligonucleotide 245. This product was digested with KpnI and BamHI and ligated into pTrc99A. Eukaryotic expression plasmids were derived from pcDNA3.1 (Invitrogen) by inserting KpnI and SalI-flanked APOBEC cDNAs from the E. coli expression plasmids. Qiagen DNA purification kits were used for small (mini)-and large (maxi)-scale plasmid purifications.
Single Cycle Infectivity Assays-293T cells were grown in Dulbecco's modified Eagle's medium (Invitrogen) containing 10% fetal bovine serum (Gemini Bioproducts), penicillin, and streptomycin (Invitrogen). HIV-GFP (also called CS-CG (31)) was produced by FuGENE 6 (Roche Applied Sciences)-mediated transfection of 50 -70% confluent 293T cells with a plasmid mixture containing 0.22 g of CS-CG, 0.14 g of pRK5/ Pack1(Gag-Pol), 0.07 g of pRK5/Rev, 0.07 g of pMDG (VSV-G Env), and 0.5 g of an APOBEC expression or empty vector control plasmid as described previously (4) . After an incubation period of 48 h, viruscontaining supernatants were clarified by low speed centrifugation, filtered (0.45 m), and quantified using a reverse transcriptase activitybased enzyme-linked immunosorbent assay (Cavidi Tech). Reverse transcriptase-normalized supernatants were applied to fresh 293T cells, and infection was allowed to proceed for 96 h. Infectivity (GFP fluorescence) was then measured by flow cytometry (FACSCalibur, BD Biosciences). For experiments requiring the recovery of retroviral DNA for hypermutation analyses, the viral supernatants were treated with 50 units/ml DNase (Sigma) prior to 293T cell infection.
Retroviral DNA Sequence Analyses-Genomic DNA was prepared from infected 293T cells using the DNeasy procedure (Qiagen) and incubated with DpnI to remove any non-reverse-transcribed CS-CG plasmid DNA. GPF was amplified using high fidelity PCR reagents (MJ Research) and CS-CG-specific primers 439 and 440 (5Ј-CG TGT ACG GTG GGA GGT CTA-3Ј and 5Ј-TT GGT AGC TGC TGT GTT GCT-3Ј). PCR products were cloned into pBluescript (Stratagene) as described previously (4) and sequenched using universal primers (University of Minnesota Advanced Genetic Analysis Center). Sequence analyses were done using Sequencher software (Gene Codes Corp.).
Virion Incorporation Assays-Viruses present in cell supernatants were harvested by filtration (0.45 m), normalized for reverse transcriptase activity as measured by enzyme-linked immunosorbent assay (Cavidi Tech), and concentrated by ultracentrifugation through a 20% sucrose cushion (Beckman SW 41 rotor, 25,000 rpm, 2 h). Pellets were dissolved in SDS loading buffer and analyzed by Western blotting. APOBEC3G was detected with a rabbit anti-APOBEC3G, C terminusspecific antibody (32) from J. Lingappa (University of Washington). p24
Gag was detected using a monoclonal antibody present in 183-H12-5C hybridoma serum. This hybridoma, originally from Drs. B. Chesebro and H. Chen, was obtained through the National Institutes of Health AIDS Research and Reference Reagent Program (catalog no. 3537).
E. coli Mutation Assays-Uracil DNA glycosylase-deficient E. coli strain BW310 was transformed with isopropyl 1-thio-␤-D-galactopyranoside-inducible APOBEC expression constructs (above) or pTrc99A. Individual colonies were picked and grown to saturation in a rich medium containing 100 g/ml ampicillin and 1 mM isopropyl 1-thio-␤-D-galactopyranoside. Appropriate dilutions were plated onto a rich medium containing 100 g/ml rifampicin or ampicillin to select Rif R colonies or measure cell viability, respectively, after an overnight incubation. Mutation frequencies were reported as the number of Rif R colonies per 10 7 viable cells. rpoB sequences were obtained by colony PCR (oligonucleotides 441 and 442, 5Ј-TTG GCG AAA TGG CGG AAA ACC-3Ј and 5Ј-C ACC GAC GGA TAC CAC CTG CTG-3Ј), Exo-SAP (USB) treatment of the PCR product, and direct DNA sequencing (30) .
RESULTS
To address whether the conserved N-terminal, C-terminal, or both cytosine deaminase domains of APOBEC3F and -3G are responsible for the observed retroviral dinucleotide hypermutation preferences, chimeric proteins were constructed by recombining the cDNA sequences at a common BsrG1 restriction site (Fig. 1A) . The resulting protein fusion junction occurs within a conserved amino acid motif (FVYS), which is predicted to lie in a region linking the two deaminase domains (25) . The resulting chimeric proteins were designated A3FϩG and A3GϩF. Should the strong dinucleotide preference of APOBEC3F or -3G be attributable to a single cytosine deaminase domain, then the dinucleotide preference would be expected to track with that domain in the corresponding chimera.
In comparison with HIV-GFP viruses produced in the presence of a control plasmid, retroviruses produced in the presence of APOBEC3F, -3G, or -3GϩF expression constructs showed much lower levels of infectivity (Fig. 1B) . In agreement with our previous studies (4), APOBEC3F was less inhibitory than APOBEC3G, causing a 40-versus 200-fold decrease in infectivity, respectively. The A3GϩF chimera decreased retroviral infectivity nearly 10-fold. This effect was smaller than that attributable to equivalent amounts of APOBEC3F or -3G, but this slight decline in chimera efficacy is perhaps not surprising given that these proteins are at least several million years diverged (chimpanzees also express both APOBEC3F and -3G (8, 24, 33, 34) ).
In contrast to the A3GϩF chimera, expression of the reciprocal A3FϩG hybrid protein failed to diminish the infectivity of HIV-GFP (Fig. 1B) . To address whether this was due to an expression and/or incorporation deficiency, we examined the protein composition of viral particles produced in the presence of A3FϩG, APOBEC3G, or a control vector after purification through a 20% sucrose cushion by ultra-centrifugation. Immunoblots of virion-associated proteins using a polyclonal antibody specific to the C terminus of APOBEC3G (32) showed that the A3FϩG chimeric protein was encapsidated nearly as well as APOBEC3G (Fig. 1C) . Levels of p24
Gag were similar in all virion preparations. Thus, the apparent lack of chimera antiretroviral activity was not attributable to an expression or incorporation deficiency. The intrinsic deamination capacity of this chimeric protein will be addressed below.
The functional A3GϩF chimera provided a molecular probe with which we could begin to delineate the deaminase domain(s) responsible for the distinct dinucleotide hypermutation preference of APOBEC3F and -3G. DNA was purified from 293T target cells infected with HIV-GFP viruses produced in the presence of APOBEC3F, -3G, -3GϩF, or an empty control vector. Virus-specific GFP DNA sequences were amplified by high fidelity PCR, cloned, and sequenced. Like retroviruses exposed to APOBEC3F and -3G, those produced in the presence of the A3GϩF chimera showed high levels of G3 A hypermutation (Fig. 1D) . As expected, the hypermutation frequencies correlated strongly with the observed infectivity declines, with APOBEC3G, -3F, and 3GϩF triggering, respectively, 208, 82, and 56 G3 A transition mutations per 10 kbp of viral DNA sequenced. The contribution from reverse transcription and PCR error was negligible inasmuch as only one base substitution (G 474 3 A) was observed in more than 10 kbp of viral DNA sequences recovered in parallel from the control infections.
The mutated positions attributable to the A3GϩF chimera were nearly identical to those of APOBEC3F (Fig. 1D) , and G 642 at which over a quarter of the A3GϩF and APOBECF hypermutations mapped. Overall, the genomic strand 5Ј-GA dinucleotide was preferred ϳ60% of the time by both A3GϩF and APOBEC3F. In contrast, APOBEC3G displayed a strong preference for 5Ј-GG and rarely triggered mutations at 5Ј-GA, as observed previously (1-4, 35) . These data are most consistent with the C-terminal cytosine deaminase domain of APOBEC3F (and by deduction APOBEC3G) being responsible for the retroviral dinucleotide hypermutation preferences observed.
To support these data, the mutational capacities and preferences of the chimeric A3FϩG and A3GϩF proteins were evaluated in an E. coli-based rifampicin-resistance (Rif R ) mutation assay (4, 30, 36) . This heterologous system provides a sensitive means to monitor the intrinsic DNA cytosine deaminase activity of the APOBEC proteins without possible complicating effects of other human and viral components. Bacteria expressing APOBEC3F and -3G were shown previously to display elevated Rif R mutation frequencies attributable to deamination within 5Ј-TC and -CC dinucleotide sequences (5Ј-GA and -GG on the complementary DNA strand), respectively (4, 30) . Similar effects were observed here with APOBEC3F and -3G expression triggering 3.4-and 7.1-fold increases in the median mutation frequency (Fig. 2A) . To our surprise, not only did expression of the A3GϩF chimera cause a 3.5-fold increase in the median frequency of Rif R , but expression of the corresponding A3FϩG chimera triggered an even larger 4.6-fold increase. This stimulation suggested that the latter chimera was indeed capable of DNA cytosine deamination, further permitting a two-way evaluation of the intrinsic mutational preferences of these hybrid proteins.
A limited number of C/G3 T/A base substitutions within a 0.2-kbp interval of the E. coli RNA polymerase B (rpoB) gene confer Rif R . Mutable cytosines can be found on either DNA stand and within all possible dinucleotide contexts. Independent Rif R mutants were therefore purified and subjected to PCR and DNA sequencing to determine the base changes responsible for the drug-resistant phenotype. The main rpoB hotspots preferred by the A3GϩF chimera were nearly identical to those preferred by APOBEC3F (C 1721 Ͼ C 1535 Ͼ G 1546 ) and were occurring at levels above those found in the control vector containing cells (Fig. 2B and supplemental Fig. 1 ). These sites harbored the majority of all Rif R mutations attributable to these proteins, and for APOBEC3F these data agreed with those from our previous studies (4). Such a correlation was even more profound for the A3FϩG chimera that, like APOBEC3G (30) , almost exclusively preferred the last cytosine of a 5Ј-CCCC run (C 1691 , Fig. 2B ). This indicated that the A3FϩG chimera was fully capable of DNA cytosine deamination. Together with the fact that the A3FϩG chimera also incorporated into retroviral particles (Fig. 1C) , these data suggested that a novel step between incorporation and cytosine deamination was disrupted, an intriguing possibility that we have begun to pursue. Moreover, these data strengthened the conclusion that the C-terminal cytosine deaminase domain aa, amino acids. B, infectivity of HIV-GFP produced in the presence of APOBEC3F (A3F), -3G (A3G), -3FϩG (A3FϩG), -3GϩF (A3GϩF), or a control vector (Vector). Results from two independent experiments were averaged and then normalized to the frequency of infection observed using viruses produced in the absence of any APOBEC protein (3.9 and 6.0% GFP-positive). Error bars report the difference in infectivity observed between the two experiments. C, immunoblots of virion-associated proteins using antibodies specific to the C terminus of APOBEC3G (upper panel) and to viral p24 Gag (lower panel). APOBEC3G and APOBEC3FϩG are predicted to be 384 and 379 amino acids, respectively, which explains their slightly different mobility. D, summary of the base substitution mutations found in HIV-GFP, which was produced in the presence of APOBEC3F, -3G, or -3GϩF (gray, white, and black circles, respectively). G3 A hypermutations and other base substitutions are depicted above and below the consensus sequence, respectively. Mutations from the indicated base to A, C, G, and T are illustrated by circles, squares, triangles, and diamonds, respectively. The consensus sequence is numbered based on the GFP gene open reading frame.
alone dictates (and presumably also catalyzes) the dinucleotide hypermutation preferences of both APOBEC3F and -3G.
However, it was still formally possible that the C-terminal cytosine deaminase domain of APOBEC3F and -3G somehow guides the N-terminal cytosine deaminase domain to the specific DNA target (i.e. selects the appropriate dinucleotide for deamination by the N-terminal deaminase domain). We therefore employed two approaches to address this possibility and distinguish it from the more likely aforementioned alternative. First, we examined the mutational capacity and specificity of an APOBEC3G mutant lacking most of its N-terminal deaminase domain (A3G⌬N(1-67) ). This deletion removed the catalytic HXE motif of the N-terminal domain. E. coli expressing this mutant showed levels and distributions of Rif R mutations indistinguishable from those attributable to expression of the full-length protein (predominantly C/G3 T/A transitions at C 1691 ; data not shown). This result demonstrated that the N-terminal deaminase domain is not required for catalysis. It is notable that a similar APOBEC3G N-terminal deletion mutant fails to restrict retroviral infectivity (37) .
Second, if the C-terminal deaminase domain alone catalyzes the lesions that result in hypermutations, then the replacement of this domain with that of another bona fide DNA cytosine deaminase should yield a chimera with the dinucleotide specificity of the latter protein. We chose to replace the Cterminal domain of APOBEC3F with AID, a single domain APOBEC protein family member that uses cytosine deamination to trigger antibody gene diversification events in vertebrates (27, 28) (Fig. 3A) . Bacterial expression of the resulting A3FϩAID chimera caused a modest 2-3-fold increase in the frequency of Rif R mutants (Fig. 3B) . However, an examination of the mutated rpoB genes revealed a striking change in the distribution of the mutations that confer Rif R ( Fig. 3C and  supplemental Fig. 1 ). The A3FϩAID chimera produced an AIDlike mutational specificity (36) , with the majority of the C/G3 T/A transition mutations occurring predominantly at two positions within rpoB, G 1586 Ͼ C 1576 . These preferences hardly overlap with those of APOBEC3F or its derivatives (Fig.  2B and supplemental Fig. 1) , indicating that the mutational specificity of the C-terminal deaminase domain of APOBEC3F ). Only the well mutated cytosines or guanines (C on the opposite strand) within rpoB are indicated. 95, 61, 22, 31, and 20 independent Rif R mutants were sequenced from cells expressing the vector control, APOBEC3G, -3F, -3FϩG, and -3GϩF, respectively. Raw sequencing data are shown in supplemental Fig. 1.   FIG. 3 . An APOBEC3F-AID chimera elicits an AID-like mutation pattern. A, schematic of the construction of the A3FϩAID chimera. The relative positions of the conserved cytosine deaminase domains are indicated by asterisks. B and C, the observed Rif R mutation frequencies (n ϭ 8) and distributions for E. coli expressing a control vector, AID, or A3FϩAID. 93 and 37 independent Rif R mutants were sequenced from cells expressing AID or A3FϩAID, respectively. The vector rpoB mutation data are identical to those shown in Fig. 2C and are illustrated again here for comparison. The experimental parameters are identical to those described in Fig. 2 . Raw sequencing data are shown in supplemental Fig. 1 . aa, amino acid(s).
can be transformed completely by replacing it with the single domain deaminase AID.
DISCUSSION
The mutation specificities of APOBEC family member chimeras and deletion mutants demonstrate that the C-terminal cytosine deaminase domain of APOBEC3F and -3G is exclusively responsible for the retroviral dinucleotide hypermutation preference and for catalysis. Respectively, these proteins prefer to deaminate cytosines within 5Ј-TC and 5Ј-CC on the retroviral cDNA strand, alterations that manifest as genomic strand 5Ј-GA3 AA and 5Ј-GG3 AG hypermutations. Such biases are readily visible in model systems and in patient-derived HIV-1 sequences. The delineation of the active cytosine deaminase domain is an important step toward fully understanding the molecular details of this mechanism of retroviral restriction.
Previous APOBEC3G site-directed mutation experiments showed that both the N-and the C-terminal cytosine deaminase domains are required for inhibiting the infectivity of HIV-based retroviruses (1, 3) . These studies used APOBEC3G variants with mutations in the conserved cytosine deaminase domain cysteine and glutamate residues thought to be crucial for zinc-binding and catalysis, respectively. Both studies reported that mutations in either deaminase domain rendered APOBEC3G unable to restrict infection, and it was therefore not possible to define the source of the deaminase activity causing retroviral hypermutation or whether other mechanistic steps were disrupted. In contrast, a third study indicated that the N-terminal glutamate was dispensable, whereas the C-terminal glutamate of APOBEC3G was essential for restricting HIV-1 infection (29) . Although this initially appears consistent with our data, both mutants still showed moderate levels of G3 A mutation suggesting that either domain can mediate catalysis (29) . This apparent conundrum may be attributable to reverse transcriptase error and/or to the APOBEC3G mutants retaining a low level of deaminase activity.
Here, functional APOBEC chimeras and deletion mutants were used to unambiguously show that, for both APOBEC3F and APOBEC3G, the C-terminal cytosine deaminase domain alone governs the catalytic activity and the retroviral hypermutation specificity. The N-terminal deaminase domain is also important for retroviral restriction, but it is likely required for mechanistic steps preceding deamination (e.g. virion incorporation (17) ). It is probable that during the evolution of this unique innate antiretroviral immune response, two single domain deaminases recombined to yield a dual domain deaminase with a target tropism and mutator activity that eventually were governed by the Nand C-terminal domains, respectively.
